Cizumab (bevacizumab biosimilar)

Lenvatinib is useful as second-line treatment after Ate/Bev for uHCC patients who do not response to Ate/Bev treatment. Changes in serum FGF-19 levels after three weeks of AteBev therapy may serve as a biomarker for selecting lenvatinib as second-line therapy.

Bevacizumab (Cizumab, Hetero Biopharma) was observed to be safe, well tolerated, lacking immunogenicity, and efficacious in the treatment of solid tumors. The findings of this phase IV study of Bevacizumab, primarily as a combination therapy regimen suggest its suitability and rationality for usage in multiple solid malignancies. CTRI/2018/4/13371 [Registered on CTRI http://ctri.nic.in/Clinicaltrials/advsearch.php : 19/04/2018]; Trial Registered Prospectively.

Patients in the sperimental arms were treated with olaparib +/- beva- cizumab (n= 788), while patients in the control arms had received placebo or standard therapies (n = 398). In clinical trials of PARPi in BRCA-related AOC, the incidence of second primary BC was low sug- gesting that intensive screening should be avoided at least in early treatment phase. Population-based data are needed to better define BC risk and surveillance strategy.